Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Summary

• Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic T-cell approval in Europe and nearing FDA approval.
• Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027.
• Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential.
• The major short-term risk is regulatory delays, meaning delays in pending regulatory milestone payments, which would likely necessitate a cash raise.

selvanegra

Thesis overview

Atara Biotherapeutics (NASDAQ:ATRA) is a commercial stage biotech developing allogeneic EBV T cells for oncology and autoimmune indications. Notably, ATRA got a world-first approval of an "off-the-shelf" allogeneic T-cell therapy (tab-cel) by EMA in December 2022 and is nearing FDA

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ATRA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.